Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

  IQVIA Holdings Inc ( IQV ) |
2013 - 2021 (9 years)

Net Revenue (Sales) is 
$12.0B (1Y +7.61% )

IQV Stock Price & Net Revenue (Sales)

Net Revenue (Sales) for IQV competitors.
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Revenue (Sales)

chevron_right 2021 $3.3B +0.3x
( +3.2% / year avg)
chevron_left 2013 $2.5B
vertical_align_top Peak $11.0B +3.4x
vertical_align_bottom Bottom $2.5B
arrow_drop_up # Up Years 8 8 of 9
years up.
arrow_drop_down # Down Years 1
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • IQV's stock price has rallied +274% from $44.04 in 2013 , or +5.8x faster than it's net revenue (sales) over the same period.
  • If IQV grows it's stock at the same rate as it's net revenue (sales) (+3.2%/year) , it's stock price will grow +137% and hit $225.69 over the next 10 years.
  • IQV's stock price has gone up 7 of the 8 years (+87%) it's net revenue (sales) were also up.
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
    1 Revenue 11359000000 11088000000 10412000000 9739000000 6878000000 5737619000 5459998000
    2 Cost of Revenue 7500000000 7300000000 6746000000 6301000000 4750000000 4136786000 3978282000
    3 Gross Profit (Income) 3859000000 3788000000 3666000000 3438000000 2128000000 1600833000 1481716000
    4 R&D 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    5 SG&A 1789000000 1734000000 1716000000 1605000000 1011000000 920985000 882338000
    6 Other Expenses 65000000.00 37000000.00 -5000000.00 -30000000.00 8000000.00 -2362000.00 8978000.00
    7 Operating Expenses 3076000000 2936000000 2857000000 2616000000 1300000000 920985000 882338000
    8 Interest Expense 416000000 447000000 414000000 346000000 144000000 101792000 100589000
    9 D&A 1287000000 1202000000 1141000000 1011000000 289000000 127742000 121013000
    10 EBITDA 2070000000 2054000000 1950000000 1833000000 1117000000 807590000 720391000
    11 Operating Income 783000000 852000000 809000000 822000000 828000000 679848000 599378000
    12 Other Income Expenses (Net) -65000000.00 -62000000.00 -75000000.00 -152000000.00 -209000000.00 -43378000.00 -10000.00
    13 Pre-Income Tax 373000000 352000000 328000000 331000000 479000000 538995000 502189000
    14 Income Tax Expense 72000000 116000000 59000000 -987000000 345000000 158989000 150056000
    15 Net Income 279000000 191000000 259000000 1309000000 115000000 387205000 356383000
    16 EPS 1.43 0.98 1.27 6.01 0.77 3.15 2.78
    17 EPS Diluted 1.43 0.96 1.24 5.88 0.76 3.08 2.72
    18 Shares Outstanding 191000000 195100000 203700000 217800000 149100000 123038000 127994000
    19 Shares Outstanding (Diluted) 191300000 199600000 208200000 222600000 152000000 125630000 131083000
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
    1 Cash & Cash Equivalents 1814000000 837000000 891000000 959000000 1198000000 977151000 867358000
    2 Short Term Investments 88000000.00 62000000.00 47000000.00 46000000.00 40000000.00 0.00 0.00
    3 Cash & S-T Investments 1902000000 899000000 938000000 1005000000 1238000000 977151000 867358000
    4 Accounts Receivables 2466000000 2638000000 2463000000 2040000000 1741000000 1199838000 1020612000
    5 Inventory 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    6 Other Current Assets 563000000 451000000 322000000 259000000 235000000 80916000 92088000
    7 Total Current Assets 5090000000 4126000000 3874000000 3450000000 3337000000 2411985000 2146083000
    8 PP&E 953000000 954000000 434000000 440000000 406000000 188393000 190297000
    9 Goodwill 12654000000 12159000000 11800000000 11850000000 10727000000 719740000 464434000
    10 Intangible Assets 5205000000 5514000000 5951000000 6591000000 6390000000 368106000 280243000
    11 Goodwill & Intangible Assets 17859000000 17673000000 17751000000 18441000000 17117000000 1087846000 744677000
    12 L-T Investments 84000000 87000000 101000000 70000000 69000000 52382000 31508000
    13 Tax Assets 114000000 119000000 109000000 98000000 89000000 42684000 35972000
    14 Other Non-Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    15 Total Non-Current Assets 19474000000 19125000000 18675000000 19292000000 17871000000 1514331000 1159749000
    16 Other Assets 1133000000.00 0.00 0.00 0.00 0.00 0.00 0.00
    17 Total Assets 24564000000 23251000000 22549000000 22742000000 21208000000 3926316000 3305832000
    18 Accounts Payables 2813000000 2512000000 437000000 322000000 250000000 145484000 108743000
    19 S-T Debt 149000000.00 100000000.00 100000000.00 103000000.00 92000000.00 48513000.00 826000.00
    20 Income Tax Payables 102000000.00 0.00 0.00 0.00 0.00 0.00 0.00
    21 Deferred Revenue 1252000000 1014000000 1007000000 733000000 774000000 584646000 543305000
    22 Other Current Liabilities 242000000 211000000 32000000 10000000 20000000 19603000 29688000
    23 Total Current Liabilities 4558000000 3945000000 3534000000 2904000000 2705000000 1594176000 1471900000
    24 L-T Debt 12384000000 11545000000 10907000000 10122000000 7108000000 2419293000 2292491000
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
    1 Net Income (Earnings) 279000000 191000000 259000000 1309000000 115000000 387205000 356383000
    2 D&A 1287000000 1202000000 1141000000 1011000000 289000000 127742000 121013000
    3 Deferred Income Tax -176000000.00 -157000000.00 -177000000.00 -1216000000.00 135000000.00 18351000.00 -6168000.00
    4 Stock-Based Compensation (SBC) 95000000 146000000 113000000 106000000 80000000 37758000 30001000
    5 Change in Working Capital 351000000 -159000000 -206000000 -86000000 -185809000 143626000 210742000
    6 Accounts Receivables 255000000.00 0.00 0.00 0.00 0.00 0.00 0.00
    7 Inventory 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    8 Accounts Payables 253000000 240000000 368000000 90000000 160000000 104350000 45804000
    9 Other Working Capital 532000000 181000000 340000000 546000000 632000000 817809000 674183000
    10 Other Non-Cash Items 18000000.00 13000000.00 11000000.00 9000000.00 30000000.00 9170000.00 6688000.00
    11 Net Cash Provided by Operating Activities 1959000000 1417000000 1254000000 970000000 860000000 475691000 431754000
    12 Investments in PP&E -616000000.00 0.00 0.00 0.00 0.00 0.00 0.00
    13 Acquisitions (Net) -177000000 -588000000 -309000000 -842000000 1887000000 32000000 -92000000
    14 Purchase of Investments -11000000.00 -25000000.00 -27000000.00 0.00 -40000000.00 -10981000.00 0.00
    15 Sales/Maturities of Investments 0.00 0.00 0.00 2000000.00 41000000.00 0.00 5861000.00
    16 Other Investing Activities -2000000.00 5000000.00 2000000.00 4000000.00 24000000.00 551000.00 -1263000.00
    17 Net Cash used for Investing Activities -796000000 -1190000000 -810000000 -1190000000 1731000000 -66955000 -173114000
    18 Debt Repayment -2499000000 -3675000000 -3061000000 -4652000000 -1951000000 -2061076000 -182769000
    19 Common Stock Issued 0.00 0.00 15000000.00 91000000.00 97000000.00 64297000.00 35228000.00
    20 Common Stock Repurchased -447000000.00 -949000000.00 -1405000000.00 -2620000000.00 -1097000000.00 -515010000.00 -415131000.00
    21 Dividends Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    22 Other Financing Activities -68000000.00 -85000000.00 -77000000.00 -54000000.00 29000000.00 14043000.00 7328000.00
    23 Net Cash Used Provided by Financing Activities -217000000 -276000000 -452000000 -72000000 -2284000000 -249246000 -130344000
    24 Net Change in Cash 977000000 -54000000 -68000000 -239000000 221000000 109793000 89215000
  • About
    Industry: Diagnostics & Research
    Sector: Healthcare
    Country: US
    IPO Date: 5/9/2013
    Stonk Exchange: NYSE
    • IQVIA Holdings, Inc
    • operates as a biotechnology company.
    • The company is headquartered in Durham, North Carolina and currently employs 58,000 full-time employees.
    • The firm operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services.
    • The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
    • The Research & Development Solutions segment provides biopharmaceutical development services.
    • The company offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design.
    • The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services.
    • The firm has its operations in the Americas, Europe and Africa, and the Asia-Pacific.